A multidisciplinary approach and patient and caregiver education lead to improved prevention and rapid resolution of ocular adverse events in ovarian cancer patients treated with mirvetuximab soravtansine.

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Giuseppa Scandurra, Valentina Lombardo, Alessandra Paggin, Filippo Marano, Giuseppe Angelico, Benito Chiofalo, Basilio Pecorino, Giuseppe Scibilia, Paolo Scollo, Alessandra Pizzo
DOI: 10.1016/j.ijgc.2025.103943
Cited by: 0

Fields of Study & Subjects

Drug-Induced Ocular Toxicity Ovarian cancer diagnosis and treatment Ocular Oncology and Treatments

Publication details

Journal / source
International Journal of Gynecological Cancer
Volume
36
Issue
2
Pages
103943–103943
Publication date
1 February 2026
Language
EN